NCT00006243 arm group 02067a263b007a8da91b15aa8480af7d [clinicaltrials_resource:NCT00006243/arm-group/02067a263b007a8da91b15aa8480af7d]
MART-1:27-35 peptide vaccine [clinicaltrials_resource:08df0a9c4b1128982b34b22ed35a32f4]gp100 antigen [clinicaltrials_resource:5847d149f0f0c99784aabdf8490f002b]laboratory biomarker analysis [clinicaltrials_resource:788bdef1603000e973c1cebc9a13c333]incomplete Freund's adjuvant [clinicaltrials_resource:df5d172b8063ce4bda85cab1a7cb6c0d]tyrosinase peptide [clinicaltrials_resource:eec622bde175cde826998c1e5ff11252]Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma [clinicaltrials:NCT00006243]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00006243 arm group 02067a263b007a8da91b15aa8480af7d [clinicaltrials_resource:NCT00006243/arm-group/02067a263b007a8da91b15aa8480af7d]
Bio2RDF identifier
NCT00006243/arm-group/02067a263b007a8da91b15aa8480af7d
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 067a263b007a8da91b15aa8480af7d
description [clinicaltrials_vocabulary:description]
Patients receive tyrosinase pe ...... weeks 0, 3, 6, 9, 12, and 24.
identifier
clinicaltrials_resource:NCT00006243/arm-group/02067a263b007a8da91b15aa8480af7d
title
NCT00006243 arm group 02067a263b007a8da91b15aa8480af7d
@en
type
label
NCT00006243 arm group 02067a26 ...... 67a263b007a8da91b15aa8480af7d]
@en